Revisión de la aplicación de la vaporización fotoselectiva en hiperplasia benigna de próstata

Palabras clave: Hiperplasia Benigna de Próstata (HPB), Resección Transuretral Prostática (RTUP), Vaporización Fotoselectiva, Eficacia

Resumen

La hiperplasia de próstata benigna (HBP) es el tumor benigno más frecuente entre los varones, alcanzando una prevalencia del 40% en la cuarta década de la vida y un 80% en hombres de 80 años a más. Esta patología conlleva a síntomas molestos e incapacitantes en el tracto urinario inferior, que en la actualidad se miden mediante el puntaje internacional de los síntomas de la próstata (IPSS). En la actualidad existen diferentes alternativas para el tratamiento quirúrgico mínimamente invasivo como lo es la vaporización fotoselectiva con green láser que puede llegar a alcanzar los mismos beneficios para el paciente en comparación con una opción de tratamiento convencional.

Métodos: Con la finalidad de conocer y describir la utilidad y seguridad de la aplicación de la vaporización fotoselectiva en pacientes con HBP, se ha realizado una búsqueda de información en las principales bases de datos: PubMed, Sciencedirect, BVS, ClinicalKey durante los últimos 10 años y se seleccionaron 11 estudios destacados.

Conclusión: La vaporización fotoselectiva con láser GreenLight es una alternativa eficaz y segura para el manejo de la sintomatología de la hiperplasia prostática benigna a corto y largo plazo y con menor riesgo de complicaciones que la RTUP.

Citas

Madersbacher S, Sampson N, Culig Z. Pathophysiology of Benign Prostatic Hyperplasia and Benign Prostatic Enlargement: A Mini-Review. Gerontology. 2019;65(5):458–64. doi: 10.1159/000496289

Castro-Díaz D, Díaz-Cuervo H, Pérez M. Hiperplasia benigna de próstata y su tratamiento: impacto en calidad de vida y función sexual. Actas Urol Esp. 2013;37(4):233–41. doi: 10.1016/j.acuro.2012.08.001

Robledo XG, Perdomo HAG. Mecanismos inflamatorios involucrados en la fisiopatología de la hiperplasia prostática benigna. Urología colombiana. 2020;29(4):240–4.

Parsons JK. Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms: Epidemiology and Risk Factors. Curr Bladder Dysfunct Rep. 2010;5(4):212–8. doi: 10.1007/s11884-010-0067-2

Sarma AV, Wei JT. Clinical practice. Benign prostatic hyperplasia and lower urinary tract symptoms. N Engl J Med. 2012;367(3):248–57. doi: 10.1056/NEJMcp1106637

Lee HW, Kim SA, Nam JW, Kim MK, Choi BY, Moon HS. The study about physical activity for subjects with prevention of benign prostate hyperplasia. Int Neurourol J. 2014;18(3):155–62. doi: 10.5213/inj.2014.18.3.155

Sausville J, Naslund M. Benign prostatic hyperplasia and prostate cancer: an overview for primary care physicians. Int J Clin Pract. 2010;64(13):1740–5. doi: 10.1111/j.1742-1241.2010.02534.x

Kapoor A. Benign prostatic hyperplasia (BPH) management in the primary care setting. Can J Urol. 2012;19 Suppl 1:10–7.

Homma Y, Gotoh M, Yokoyama O, Masumori N, Kawauchi A, Yamanishi T, et al. Outline of JUA clinical guidelines for benign prostatic hyperplasia. Int J Urol. 2011;18(11):741–56. doi: 10.1111/j.1442-2042.2011.02860.x

Vuichoud C, Loughlin KR. Benign prostatic hyperplasia: epidemiology, economics and evaluation. Can J Urol. 2015;22 Suppl 1:1–6.

Parsons JK, Dahm P, Köhler TS, Lerner LB, Wilt TJ. Surgical Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline Amendment 2020. J Urol. 2020;204(4):799–804. doi: 10.1097/JU.0000000000001298

Andrés G, Arance I, Gimbernat H, Redondo C, García-Tello A, Angulo JC. Laser transurethral resection of the prostate: Safety study of a novel system of photoselective vaporization with high power diode laser in prostates larger than 80mL. Actas Urol Esp. 2015;39(6):375–82. doi: 10.1016/j.acuro.2014.10.007

Rodríguez Reina G, Vázquez Alba D, Martínez-Salamanca JI, Carballido Rodríguez J. Hiperplasia benigna de próstata. Medicine. 2011;10(83):5628–41.

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol. 2014;65(1):124–37. doi: 10.1016/j.eururo.2013.09.046

Sountoulides P, Kaufmann O, Kikidakis D, Pardalidis N. Vaporización fotoselectiva de la próstata (VFP) vs enucleacion de la próstata con láser holmio (HOLEP): resultados actuales y estrategias. Archivos Españoles de Urología. 2010;63(2):89–101.

Malek RS, Barrett DM, Kuntzman RS. High-power potassium-titanyl-phosphate (KTP/532) laser vaporization prostatectomy: 24 hours later. Urology. 1998;51(2):254–6. doi: 10.1016/s0090-4295(97)00613-4

Kuromatsu I, Imamura T, Sugimura Y. [Photoselective vaporization of the prostate (PVP) using 80 watt high power potassium-titanyl-phosphate (KTP) laser for benign prostatic hyperplasia: the first fifty-seven patients in Japan]. Nihon Hinyokika Gakkai Zasshi. 2006;97(7):815–22. doi: 10.5980/jpnjurol1989.97.815

Woo H, Reich O, Bachmann A, Choi B, Collins E, Rosette J de la, et al. Outcome of GreenLight HPS 120-W Laser Therapy in Specific Patient Populations: Those in Retention, on Anticoagulants, and with Large Prostates (≥ 80 ml). European Urology Supplements. 2008;7(4):378–83. doi: 10.1016/j.eursup.2008.01.016

Zhou Y, Xue B, Mohammad NA, Chen D, Sun X, Yang J, et al. Greenlight high-performance system (HPS) 120-W laser vaporization versus transurethral resection of the prostate for the treatment of benign prostatic hyperplasia: a meta-analysis of the published results of randomized controlled trials. Lasers Med Sci. 2016;31(3):485–95. doi: 10.1007/s10103-016-1895-x

Bachmann A, Muir GH, Collins EJ, Choi BB, Tabatabaei S, Reich OM, et al. 180-W XPS GreenLight laser therapy for benign prostate hyperplasia: early safety, efficacy, and perioperative outcome after 201 procedures. Eur Urol. 2012;61(3):600–7. doi: 10.1016/j.eururo.2011.11.041

NICE Guidance. GreenLight XPS for treating benign prostatic hyperplasia: © NICE (2016) GreenLight XPS for treating benign prostatic hyperplasia. BJU Int. 2017;119(6):823–30. doi: 10.1111/bju.13897

Ajib K, Mansour M, Zanaty M, Alnazari M, Hueber P-A, Meskawi M, et al. Photoselective vaporization of the prostate with the 180-W XPS-Greenlight laser: Five-year experience of safety, efficiency, and functional outcomes. Can Urol Assoc J. 2018;12(7):E318–24. doi: 10.5489/cuaj.4895

Piotrowicz G, Syryło T, Jedynak R, Zieliński H. Efficacy and Safety of Photoselective Vaporization of the Prostate with 120 W 532 nm Laser in Patients with Benign Prostatic Hyperplasia on Anticoagulation or Antiplatelet Therapy: Observations on Long-Term Outcomes. Photomed Laser Surg. 2018;36(5):273–83. doi: 10.1089/pho.2017.4367

Meskawi M, Hueber P-A, Valdivieso R, Bruyere F, Misrai V, Fournier G, et al. Multicenter international experience of 532 nm-laser photo-vaporization with Greenlight XPS in men with large prostates (prostate volume > 100 cc). World J Urol. 2017;35(10):1603–9. doi: 10.1007/s00345-017-2007-7

Valdivieso R, Hueber P-A, Meskawi M, Belleville E, Ajib K, Bruyere F, et al. Multicentre international experience of 532-nm laser photoselective vaporization with GreenLight XPS in men with very large prostates. BJU Int. 2018;122(5):873–8. doi: 10.1111/bju.14208

Castellani D, Cindolo L, Nunzio CD, Rosa MD, Greco F, Gasparri L, et al. Comparison Between Thulium Laser VapoEnucleation and GreenLight Laser Photoselective Vaporization of the Prostate in Real-Life Setting: Propensity Score Analysis. Urology. 2018;121:147–52. doi: 10.1016/j.urology.2018.09.007

Peng L, Zheng X-N, Wu J-P, Zeng X, He Q, Chen G, et al. Holmium laser technologies versus photoselective greenlight vaporization for patients with benign prostatichyperplasia: a meta-analysis. Lasers Med Sci. 2020;35(7):1441–50. doi: 10.1007/s10103-020-02953-z

Zang Yc, Deng Xx, Yang Dr, Xue Bx, Xu Lj, Xl L, et al. Photoselective vaporization of the prostate with GreenLight 120-W laser versus transurethral resection of the prostate for benign prostatic hyperplasia: a systematic review with meta-analysis of randomized controlled trials. Lasers Med Sci. 2015;31(2):235–40. doi: 10.1007/s10103-015-1843-1

Thomas JA, Tubaro A, Barber N, d’Ancona F, Muir G, Witzsch U, et al. A Multicenter Randomized Noninferiority Trial Comparing GreenLight-XPS Laser Vaporization of the Prostate and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Obstruction: Two-yr Outcomes of the GOLIATH Study. Eur Urol. 2016;69(1):94–102. doi: 10.1016/j.eururo.2015.07.054

Cornu J-N, Ahyai S, Bachmann A, de la Rosette J, Gilling P, Gratzke C, et al. A Systematic Review and Meta-analysis of Functional Outcomes and Complications Following Transurethral Procedures for Lower Urinary Tract Symptoms Resulting from Benign Prostatic Obstruction: An Update. Eur Urol. 2015;67(6):1066–96. doi: 10.1016/j.eururo.2014.06.017

Lai S, Peng P, Diao T, Hou H, Wang X, Zhang W, et al. Comparison of photoselective green light laser vaporisation versus traditional transurethral resection for benign prostate hyperplasia: an updated systematic review and meta-analysis of randomised controlled trials and prospective studies. BMJ Open. 2019 Aug 21;9(8):e028855. doi: 10.1136/bmjopen-2018-028855

Vasudeva P, Kumar N, Kumar A, Kumar G, Patel M, Gupta P. Impact of monopolar TURP, bipolar TURP and photoselective vaporization of prostate for enlarged prostate on erectile function. Low Urin Tract Symptoms. 2019 Jan;11(1):24–9. doi: 10.1111/luts.12189

Publicado
2021-07-30
Sección
Artículos de revisión